Curaleaf Holdings (CURLF) Tax Provisions (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Tax Provisions of $98.7 million for Q1 2026, up 393.3% year-on-year from $20.0 million in Q1 2025, and down 55.57% on a QoQ basis from $222.2 million in Q4 2025.
Curaleaf Holdings (CURLF) Tax Provisions (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Tax Provisions for 8 consecutive years, with $98.7 million the latest figure, recorded in Q1 2026.
- Quarterly Tax Provisions rose 393.3% year-over-year to $98.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259.2 million (up 147.64% YoY) and the FY2025 annual result came in at $123.7 million, up 25.89% from the prior year.
- Tax Provisions slipped to $98.7 million in Q1 2026 per CURLF's latest filing, from $222.2 million in the prior quarter.
- Over the last five years, Tax Provisions for CURLF reached as high as $3.0 billion in Q4 2023 and fell as low as -$50.0 million in Q3 2022.
- A 5-year average of $178.1 million and a median of -$31.9 million in 2023 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2023 — Tax Provisions soared 22084.03% — and 2024, when it sank 93.2%.
- Year by year, Tax Provisions stood at -$13.5 million in 2022, then surged by 22084.03% to $3.0 billion in 2023, then plunged by 93.2% to $202.3 million in 2024, then climbed by 9.82% to $222.2 million in 2025, then tumbled by 55.57% to $98.7 million in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $98.7 million, $222.2 million, and -$30.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 67.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 157.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 676.90 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -423.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 48.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 30.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | 98.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.71 Mn |
| Dec 31, 2025 | 222.16 Mn |
| Sep 30, 2025 | -30.24 Mn |
| Jun 30, 2025 | -31.38 Mn |
| Mar 31, 2025 | -33.65 Mn |
| Dec 31, 2024 | 202.30 Mn |
| Sep 30, 2024 | -32.57 Mn |
| Jun 30, 2024 | -31.39 Mn |
| Mar 31, 2024 | -40.09 Mn |
| Dec 31, 2023 | 2.97 Bn |
| Sep 30, 2023 | -31.86 Mn |
| Jun 30, 2023 | -41.95 Mn |
| Mar 31, 2023 | -40.73 Mn |
| Dec 31, 2022 | -13.53 Mn |
| Sep 30, 2022 | -49.97 Mn |
| Jun 30, 2022 | -49.16 Mn |
| Mar 31, 2022 | -43.14 Mn |
| Dec 31, 2021 | -35.13 Mn |
| Sep 30, 2021 | -60.31 Mn |
| Jun 30, 2021 | -42.62 Mn |